A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2023-06-24
Adverse events
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-01 (study day 26); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-12 (study day 68); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-26 (study day 82); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2024-01-04 (study day 182); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-02-17 (study day 226); relationship: not assessed
Data queries
No data queries.